Industries > Pharma > Nonalcoholic Steatohepatitis (NASH) Market Report to 2027

Back to Pharma Reports

Nonalcoholic Steatohepatitis (NASH) Market Report to 2027

Name: Visiongain
Address: Airport House, Surrey, London, CR0 0XZ, United Kingdom
Telephone: +44 (0) 20 7549 9987

Forecasts and Analysis by Therapeutics (GFT 505, Obeticholic Acid (INT-747), Simtuzumab and Liraglutide (Victoza), Vitamin E, Pioglitazone, Placebo) and Region

PUBLISHED: 01 December 2017

PAGES: 145

PRODUCT CODE: PHA0263

SUBMARKET: Pharma Therapeutic Drugs

SKU: PHA0263 Categories: Pharma, Pharma, Therapeutic Drugs

• Do you need definitive NASH market data?
• Succinct NASH market analysis?
• Technological insight?
• Actionable business recommendations?

Read on to discover how this definitive report can transform your own research and save you time.

The increase in prevalence of hepatic pathology and its pathophysiology have propelled the growth of the novel therapeutic studies, which has given birth to the novel therapeutic solutions such as Farnesoid X Receptor (FXR) agonists, incretins and probiotics. Most of these studies are in last phase of their clinical trials and commercialization is expected within a short period of time that could be used in treating patients with NASH.

Report highlights

• 132 quantitative tables, charts, and graphs across 145 pages

• Global NASH market outlook and analysis from to 2027

• Global NASH submarket forecasts and analysis from to 2027
• GFT 505
• Obeticholic Acid (INT-747)
• Simtuzumab and Liraglutide (Victoza)
• Vitamin E
• Pioglitazone
• Placebo

• Regional and National NASH market forecasts to 2027
• North America forecast to 2027:
• US forecast to 2027
• Canada forecast to 2027
• Mexico forecast to 2027

• South America forecast to 2027:
• Brazil forecast to 2027
• Argentina forecast to 2027
• Paraguay forecast to 2027
• Bolivia forecast to 2027
• Rest of South America forecast to 2027

• Europe forecast to 2027:
• Germany forecast to 2027
• UK forecast to 2027
• France forecast to 2027
• Italy forecast to 2027
• Spain forecast to 2027
• Rest of Europe forecast to 2027

• Asia-Pacific forecast to 2027
• Japan forecast to 2027
• India forecast to 2027
• China forecast to 2027
• Australia forecast to 2027
• Thailand forecast to 2027
• Rest of Asia-Pacific forecast to 2027

• Rest of World forecast to 2027:
• Middle East forecast to 2027
• Africa forecast to 2027
• Other Countries forecast to 2027

Key questions answered
• What does the future hold for the Pharmaceutical industry with regards to Nonalcoholic Steatohepatitis (NASH)
• Where should you target your business strategy?
• Which applications should you focus upon?
• Which disruptive technologies should you invest in?
• Which companies should you form strategic alliances with?
• Which company is likely to success and why?
• What business models should you adopt?
• What industry trends should you be aware of?

Target audience
• Leading Pharmaceutical companies
• Suppliers
• Contractors
• Technologists
• R&D staff
• Consultants
• Analysts
• CEO’s
• CIO’s
• COO’s
• Business development managers
• Investors
• Governments
• Agencies
• Banks

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

1. Report Overview

1.1 NASH Market Overview

1.2 Research Methodology

1.3 Primary Research

1.4 Secondary Research

1.5 Market Evaluation & Forecasting Methodology

1.6 Global NASH Market Segmentation

1.7 Overview of Findings

1.8 Why You Should Read This Report

1.9 How this report delivers

1.10 Key Questions Answered by this Analytical Report

1.11 Frequently Asked Questions (FAQ)

1.12 Who is This Report For?

1.13 Associated Visiongain Reports

1.14 About Visiongain

2. Introduction to NASH Market

2.1 Dos and Don’ts for NASH

2.2 Alcohol Intake

2.3 Use of Statin

2.4 Use of Hepatotoxic Drugs

2.5 Vaccination for Hepatitis A and B

3. NASH Market Forecast to 2027

4. NASH Market by Therapeutics: Market Forecast to 2027

4.1 Overview

4.2 GFT 505

4.2.1 Competitive Scenario

4.3 Obeticholic Acid (INT-747)

4.3.1 Competitive Scenario

4.4 Simtuzumab and Liraglutide (Victoza)

4.5.1 Competitive scenario

4.5 Vitamin E

4.5.1 Competitive Scenario

4.6 Pioglitazone

4.6.1 Competitive Scenario

4.7 Placebo

5. Regional NASH Market Forecasts to 2027

5.1 Regional NASH Market Forecast 2017-2027

5.2 North American NASH Market Forecast 2017-2027

5.2.1 USA NASH Market Forecast 2017-2027

5.2.2 Canada NASH Market Forecast 2017-2027

5.2.3 Mexico NASH Market Forecast 2017-2027

5.3 South American NASH Market Forecast 2017-2027

5.3.1 Brazil NASH Market Forecast 2017-2027

5.3.2 Argentina NASH Market Forecast 2017-2027

5.3.3 Paraguay NASH Market Forecast 2017-2027

5.3.4 Bolivia NASH Market Forecast 2017-2027

5.3.5 Rest of South America NASH Market Forecast 2017-2027

5.4 European NASH Market Forecast 2017-2027

5.4.1 France NASH Market Forecast 2017-2027

5.4.2 Germany NASH Market Forecast 2017-2027

5.4.3 UK NASH Market Forecast 2017-2027

5.4.4 Spain NASH Market Forecast 2017-2027

5.4.5 Italy NASH Market Forecast 2017-2027

5.4.6 Rest of Europe NASH Market Forecast 2017-2027

5.5 Asia-Pacific NASH Market Forecast 2017-2027

5.5.1 China NASH Market Forecast 2017-2027

5.5.2 Japan NASH Market Forecast 2017-2027

5.5.3 India NASH Market Forecast 2017-2027

5.5.4 Australia NASH Market Forecast 2017-2027

5.5.5 Thailand NASH Market Forecast 2017-2027

5.5.6 Rest of Asia-Pacific NASH Market Forecast 2017-2027

5.6 Rest of World NASH Market Forecast 2017-2027

5.6.1 Middle East NASH Market Forecast 2017-2027

5.6.2 Africa NASH Market Forecast 2017-2027

5.6.3 Other Countries NASH Market Forecast 2017-2027

6. NASH Market, Qualitative Analysis, 2017-2027

6.1 Porter’s Five Forces Analysis of the NASH Market

6.1.1 Bargaining Power of Buyers (Low)

6.1.2 Bargaining Power of Suppliers (Medium)

6.1.3 Threat of New Entrants (Low)

6.1.4 Threat of Substitute Products (Medium)

6.1.5 Intensity of Competitive Rivalry (Low)

6.2 Market Dynamics

6.3 Drivers

6.3.1 Rampant Growth Rate Of Obesity And Diabetes Globally

6.3.2 Acceleration in Initiatives For Research And Development Activities

6.4 Restraints

6.4.1 Slower Development Of Therapeutics for NASH

6.4.2 Blurred Understanding of Pathophysiology of NASH

6.4.3 Inefficient Diagnostic Technology for NASH

6.5 Opportunities

6.5.1 Biomarker technologies in diagnosis of NASH

7. Leading Companies in NASH Market

7.1 AstraZeneca Plc

7.1.1 AstraZeneca Plc: Company Overview

7.1.2 AstraZeneca Plc: Product Portfolio

7.2 Intercept Pharmaceuticals, Inc.

7.2.1 Intercept Pharmaceuticals, Inc.: Company Overview

7.2.2 Intercept Pharmaceuticals, Inc.: Recent Developments

7.3 GENFIT SA

7.3.1 GENFIT SA: Company Overview

7.3.2 GENFIT SA: Product Portfolio

7.4 Gilead Sciences, Inc.

7.4.1 Gilead Sciences, Inc.: Company Overview

7.4.2 Gilead Sciences, Inc.: Product Portfolio

7.4.3 Gilead Sciences, Inc.: Recent Developments

7.5 Merck & Co. Inc.

7.5.1 Merck & Co. Inc.: Company Overview

7.5.2 Merck & Co. Inc.: Product Portfolio

7.5.3 Merck & Co. Inc.: Recent Developments

7.6 Novartis AG

7.6.1 Novartis AG: Company Overview

7.6.2 Novartis AG: Product Portfolio

7.6.3 Novartis AG: Recent Developments

7.7 Bristol-Myers Squibb

7.7.1 Bristol-Myers Squibb: Company Overview

7.7.2 Bristol-Myers Squibb: Product Portfolio

7.8 Galmed Pharmaceuticals Ltd.

7.8.1 Galmed Pharmaceuticals Ltd.: Company Overview

7.8.2 Galmed Pharmaceuticals Ltd.: Recent Developments

7.9 Immuron Limited

7.9.1 Immuron Limited: Company Overview

7.10 Novo Nordisk AG

7.10.1 Novo Nordisk AG: Company Overview

7.10.2 Novo Nordisk AG: Product Portfolio

7.11 Other Companies of Interest in the NASH Market

8. Conclusions

8.1 Current Leading Segments

8.2 Leading Regional Markets

8.3 Emerging Markets

8.4 The Future of the Market?

9. Glossary

Associated Visiongain Reports

Visiongain Report Sales Order Form

Appendix A

About Visiongain

Appendix B

Visiongain report evaluation form

List of Figures

Figure 3.1 NASH Market, by Therapeutics, ($m), 2017-2027

Figure 4.1 NASH Market, by Therapeutics, Market Share (%), 2016

Figure 4.2 NASH Market, by Therapeutics, Forecast ($m) 2017-2027

Figure 4.3 Global GFT 505 for NASH Market Forecast, by Geography, ($m) 2017-2027

Figure 4.4 Global Obeticholic Acid (INT-747) for NASH Market Forecast, by Geography, ($m) 2017-2027

Figure 4.5 Global Simtuzumab and Liraglutide (Victoza) for NASH Market Forecast, by Geography, ($m) 2017-2027

Figure 4.6 Global Vitamin E for NASH Market Forecast, by Geography, ($m) 2017-2027

Figure 4.7 Global Pioglitazone for NASH Market Forecast, by Geography, ($m) 2017-2027

Figure 4.8 Global Placebo for NASH Market Forecast, by Geography, ($m) 2017-2027

Figure 5.1 Global NASH Market Forecast, by Geography, by Geography ($m) 2017-2027

Figure 5.2 Global NASH Market Forecast, by Geography, Market Share (%), 2016

Figure 5.3 North America NASH Market Forecast, by Country ($m) 2017-2027

Figure 5.4 North America NASH Market, by Country, Market Share (%), 2016

Figure 5.5 USA NASH Market Forecast ($m) 2017-2027

Figure 5.6 Canada NASH Market Forecast ($m) 2017-2027

Figure 5.7 Mexico NASH Market Forecast ($m) 2017-2027

Figure 5.8 South America NASH Market Forecast, by Country ($m) 2017-2027

Figure 5.9 South America NASH Market, by Country, Market Share (%), 2016

Figure 5.10 Brazil NASH Market Forecast ($m) 2017-2027

Figure 5.11 Argentina NASH Market Forecast ($m) 2017-2027

Figure 5.12 Paraguay NASH Market Forecast ($m) 2017-2027

Figure 5.13 Bolivia NASH Market Forecast ($m) 2017-2027

Figure 5.14 Rest of South America NASH Market Forecast ($m) 2017-2027

Figure 5.15 Europe NASH Market Forecast, by Country ($m) 2017-2027

Figure 5.16 Europe NASH Market, by Country, Market Share (%), 2016

Figure 5.17 France NASH Market Forecast ($m) 2017-2027

Figure 5.18 Germany NASH Market Forecast ($m) 2017-2027

Figure 5.19 UK NASH Market Forecast ($m) 2017-2027

Figure 5.20 Spain NASH Market Forecast ($m) 2017-2027

Figure 5.21 Italy NASH Market Forecast ($m) 2017-2027

Figure 5.22 Rest of Europe NASH Market Forecast ($m) 2017-2027

Figure 5.23 Asia-Pacific NASH Market Forecast, by Country ($m) 2017-2027

Figure 5.24 Asia-Pacific NASH Market, Market Share (%), 2016

Figure 5.25 China NASH Market Forecast ($m) 2017-2027

Figure 5.26 Japan NASH Market Forecast ($m) 2017-2027

Figure 5.27 India NASH Market Forecast ($m) 2017-2027

Figure 5.28 Australia NASH Market Forecast ($m) 2017-2027

Figure 5.29 Thailand NASH Market Forecast ($m) 2017-2027

Figure 5.30 Rest of Asia-Pacific NASH Market Forecast ($m) 2017-2027

Figure 5.31 RoW NASH Market Forecast, by Country ($m) 2017-2027

Figure 5.32 Rest of World NASH Market, by Country, Market Share (%), 2016

Figure 5.33 Middle East NASH Market Forecast ($m) 2017-2027

Figure 5.34 Africa NASH Market Forecast ($m) 2017-2027

Figure 5.35 Other Countries NASH Market Forecast ($m) 2017-2027

Figure 6.1 Porter’s Five Forces Analysis of the NASH Market

Figure 6.2 Number of Incidences of Diabetes Globally, by Geography (2000, 2011 & 2030)

Figure 7.1 AstraZeneca Plc, Revenue, ($million), 2012-2016

Figure 7.2 AstraZeneca Plc, Product Segments Share (%), 2016

Figure 7.3 Intercept Pharmaceuticals, Inc., Revenue, ($million), 2012-2016

Figure 7.4 GENFIT SA, Revenue, ($million), 2012-2016

Figure 7.5 Gilead Sciences, Inc., Revenue, ($million), 2012-2016

Figure 7.6 Gilead Sciences, Inc., Product Segments Share (%), 2016

Figure 7.7 Gilead Sciences, Inc., Geographical Presence Share (%), 2016

Figure 7.8 Merck & Co. Inc., Revenue, ($million), 2012-2016

Figure 7.9 Merck & Co. Inc., Product Segments Share (%), 2016

Figure 7.10 Merck & Co. Inc., Geographical Presence Share (%), 2016

Figure 7.11 Novartis AG, Revenue, ($million), 2012-2016

Figure 7.12 Novartis AG, Product Segments Share (%), 2016

Figure 7.13 Novartis AG, Geographical Presence Share (%), 2016

Figure 7.14 Bristol-Myers Squibb, Revenue, ($million), 2012-2016

Figure 7.15 Bristol-Myers Squibb, Product Segments Share (%), 2016

Figure 7.16 Bristol-Myers Squibb, Geographical Presence Share (%), 2016

Figure 7.17 Novo Nordisk AG, Revenue, ($million), 2012-2016

Figure 8.1 World NASH, by Therapeutics, ($m), 2017-2027

Figure 8.2 World NASH, by Geography, ($m), 2017-2027

List of Tables

Table 3.1. NASH Market Forecast ($m, AGR%, CAGR%) 2017-2027

Table 4.1. NASH Market Forecast, by Therapeutics ($m, AGR%, CAGR%) 2017-2027

Table 4.2 Global GFT 505 for NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 4.3 Global GFT 505 for NASH Market Forecast, by Geography, ($m, AGR%, CAGR%) 2017-2027

Table 4.4 Global Obeticholic Acid (INT-747) for NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 4.5 Global Obeticholic Acid (INT-747) for NASH Market Forecast, by Geography ($m, AGR%, CAGR%) 2017-2027

Table 4.6 Global Simtuzumab and Liraglutide (Victoza) for NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 4.7 Global Simtuzumab and Liraglutide (Victoza) for NASH Market Forecast, by Geography ($m, AGR%, CAGR%) 2017-2027

Table 4.8 Global Vitamin E for NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 4.9 Global Vitamin E for NASH Market Forecast, by Geography ($m, AGR%, CAGR%) 2017-2027

Table 4.10 List of Key Pioglitazone Brands Available in the Market

Table 4.11 Global Pioglitazone for NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 4.12 Global Pioglitazone for NASH Market Forecast, by Geography ($m, AGR%, CAGR%) 2017-2027

Table 4.13 Global Placebo for NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 4.14 Global Placebo for NASH Market Forecast, by Geography ($m, AGR%, CAGR%) 2017-2027

Table 5.1 NASH Market Forecast, by Geography ($m, AGR%, CAGR%) 2017-2027

Table 5.2 North America NASH Market Forecast, by Country ($m, AGR%, CAGR%) 2017-2027

Table 5.3 USA NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 5.4 Canada NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 5.5 Mexico NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 5.6 South America NASH Market Forecast, by Country ($m, AGR%, CAGR%) 2017-2027

Table 5.7 Brazil NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 5.8 Argentina NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 5.9 Paraguay NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 5.10 Bolivia NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 5.11 Rest of South America NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 5.12 European NASH Market Forecast, by Country ($m, AGR%, CAGR%) 2017-2027

Table 5.13 France NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 5.14 Germany NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 5.15 UK NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 5.16 Spain NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 5.17 Italy NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 5.18 Rest of European NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 5.19 Asia-Pacific NASH Market Forecast, by Country ($m, AGR%, CAGR%) 2017-2027

Table 5.20 China NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 5.21 Japan NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 5.22 India NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 5.23 Australia NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 5.24 Thailand NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 5.25 Rest of Asia-Pacific NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 5.26 Rest of World NASH Market Forecast, by Country ($m, AGR%, CAGR%) 2017-2027

Table 5.27 Middle East NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 5.28 Africa NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 5.29 Other Countries NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027

Table 7.1 AstraZeneca Plc: Company Overview

Table 7.2 AstraZeneca Plc: Product Portfolio

Table 7.3 Intercept Pharmaceuticals, Inc.: Company Overview

Table 7.4 Intercept Pharmaceuticals, Inc.: Recent Developments

Table 7.5 GENFIT SA: Company Overview

Table 7.6 GENFIT SA: Product Portfolio

Table 7.7 Gilead Sciences, Inc.: Company Overview

Table 7.8 Gilead Sciences, Inc.: Product Portfolio

Table 7.9 Gilead Sciences, Inc.: Recent Developments

Table 7.10 Merck & Co. Inc.: Company Overview

Table 7.11 Merck & Co. Inc.: Product Portfolio

Table 7.12 Merck & Co. Inc.: Recent Developments

Table 7.13 Novartis AG: Company Overview

Table 7.14 Novartis AG: Product Portfolio

Table 7.15 Novartis AG: Recent Developments

Table 7.16 Bristol-Myers Squibb: Company Overview

Table 7.17 Bristol-Myers Squibb : Product Portfolio

Table 7.18 Galmed Pharmaceuticals Ltd.: Company Overview

Table 7.19 Galmed Pharmaceuticals Ltd.: Recent Developments

Table 7.20 Immuron Limited: Company Overview

Table 7.21 Novo Nordisk AG: Company Overview

Table 7.22 Novo Nordisk AG: Product Portfolio

Table 7.23 Other Companies of Interest in the NASH Market

Abbott Laboratories

AbbVie, Inc.

Alkermes Plc

Amarin Corp. Plc

Amgen, Inc.

Amnis Corporation

Array BioPharma, Inc.

Associates Of Cape Cod Inc.

Astex Pharmaceuticals Inc.

AstraZeneca Plc

ASYMPTOTE LTD

Bayer AG

Bayer Corporation

Bayer HealthCare AG

Bayer Schering Pharma Aktiengesellschaft

BioLife Solutions, Inc.

BioMarin Pharmaceutical, Inc.

Biotest AG

Bristol-Myers Squibb Co.

Cardax, Inc.

Cardinal Health, Inc.

Ceapro, Inc.

Celgene Corp.

Cephalon, Inc.

Chugai Pharmaceutical Co., Ltd.

CK Life Sciences International (Holdings), Inc.

Consensys Imaging Service Inc.

Cornerstone Research & Development Inc.

Crescendo Bioscience, Inc.

CTI BioPharma Corp.

Deroyal Industries Inc.

Domain Therapeutics SA

Emd Millipore Corporation

Emd Serono Inc.

Endo International Plc

Evotec AG

Galderma Sa

Galmed Pharmaceuticals Ltd.

GE HEALTHCARE LTD

Genfit SA

Gilead Sciences, Inc.

Henry Schein, Inc.

Illumina, Inc.

Immuron Limited

Intercept Pharmaceuticals, Inc.

Janssen Biotech, Inc.

JHL Biotech, Inc.

Johnson & Johnson

Laboratoire Theramex

Laboratory Corp. of America Holdings

LifeWatch AG

Lombard Medical, Inc.

Lonza Group AG

McKesson Corp.

Medline Industries Inc.

Medtronic Plc

Merck & Co., Inc.

Merck KGaA

MorphoSys AG

Motion Picture And Television Fund

Myrexis, Inc.

Myriad Genetics, Inc.

National Cancer Institute

NBTY, Inc.

Nexvet Biopharma PLC

Northwell Health Inc.

Novartis AG

Novartis AG

Novo Nordisk AG

Opexa Therapeutics, Inc.

Otsuka Pharmaceutical Co. Ltd.

Owens & Minor, Inc.

Panacos Pharmaceuticals, Inc.

PELICAN HEALTHCARE LTD

Pfizer Inc.

Polymer Technology Systems Inc.

Progyny Inc.

Quanterix Corp.

Quest Diagnostics, Inc.

Smith & Nephew Plc

Vertex Pharmaceuticals, Inc.

Windtree Therapeutics, Inc.

List of Organizations

China Food and Drug Administration

NHS

NICE

Stanford University

US Center for Disease Prevention and Control (CDC)

US Food and Drug Administration

World Bank

Download sample pages

Complete the form below to download your free sample pages for Nonalcoholic Steatohepatitis (NASH) Market Report to 2027

Download sample pages

Complete the form below to download your free sample pages for Nonalcoholic Steatohepatitis (NASH) Market Report to 2027

Case studies

Need customized work?

Report overview

Methodology

Reports catalogue

Would you like to get the latest Visiongain pharma reports catalogue?

What are the dynamic growth sectors? where are the regional business opportunities?

Which technologies will prevail and who are the leading companies succeeding in these sectors and why?

If you want definitive answers to business critical questions, discover Visiongain’s full range of business intelligence reports.

If so, please email Sara Peerun on sara.peerun@visiongain.com or call her today on +44 (0) 20 7549 9987

Pharmaceutical industry associations

American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Free Visiongain Report

Connect with us

Visiongain Pharma

Latest Pharma news

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

READ

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

READ

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

READ

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031

Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.

01 April 2021

READ

Industries > Pharma > Nonalcoholic Steatohepatitis (NASH) Market Report to 2027

Back to Pharma Reports

Nonalcoholic Steatohepatitis (NASH) Market Report to 2027

Forecasts and Analysis by Therapeutics (GFT 505, Obeticholic Acid (INT-747), Simtuzumab and Liraglutide (Victoza), Vitamin E, Pioglitazone, Placebo) and Region

Download sample pages

Download sample pages

Connect with us

Latest Pharma news

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

Visiongain Publishes Cell-Based Assays Market Report to 2030

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031

Categories

Our Clients